Thyroid Transcription Factor-1 (TTF-1)

TTF-1 is a protein found inside the nuclei of cells in the thyroid gland and in certain lung cells. Pathologists test for it in tumor tissue using a stain called immunohistochemistry. A positive TTF-1 result usually points to a cancer arising from the lung (most often adenocarcinoma) or thyroid, while mesothelioma is almost always TTF-1 negative.

Origin

TTF-1 was identified in the late 1980s by Roberto Di Lauro and colleagues studying thyroid gene regulation, and was later shown to also be expressed in lung tissue. The gene is now formally named NKX2-1. It became a standard diagnostic stain in lung and mesothelioma pathology in the 1990s and 2000s.

Significance in Asbestos Context

For an asbestos-exposed patient with a tumor in the chest, distinguishing pleural mesothelioma from a lung adenocarcinoma that has spread to the pleura is one of the most important diagnostic steps. The two diseases have different treatments, prognoses, and legal claim pathways. TTF-1 is one of the key markers pathologists use to make that call: mesothelioma is essentially always TTF-1 negative, while roughly 70–80% of lung adenocarcinomas are TTF-1 positive. A TTF-1 positive result generally moves the diagnosis toward lung cancer (which can still be asbestos-related), while a TTF-1 negative tumor with positive mesothelial markers supports mesothelioma. Because both diseases are compensable when linked to asbestos exposure, the specific diagnosis affects which trust funds, claim types, and medical treatments are available.

Example Sentence

The biopsy report noted that the tumor cells were TTF-1 negative and calretinin positive, supporting a diagnosis of pleural mesothelioma rather than metastatic lung adenocarcinoma.

Related Terms

Immunohistochemistry, Calretinin, WT-1, Adenocarcinoma, Mesothelioma, Napsin A

Notes

• Ask your pathologist or oncologist for a copy of the full immunohistochemistry panel. TTF-1 should be reported alongside mesothelial markers (calretinin, WT-1, D2-40) and other carcinoma markers (Napsin A, Ber-EP4, MOC-31) before a final diagnosis is made.
• A single marker is not enough; the Helsinki Criteria and CAP guidelines recommend at least two positive mesothelial markers and two negative carcinoma markers (or vice versa) to confirm the diagnosis.
• If your diagnosis is uncertain or the panel is limited, request a second-opinion review at a mesothelioma referral center such as the U.S. or International Mesothelioma Panel. Misclassification between lung adenocarcinoma and mesothelioma is well documented.
• Preserve the original pathology slides and tissue blocks (not just the report); future testing, expert review, and legal claims often depend on having the actual material available.
• A small percentage of mesotheliomas can show focal TTF-1 staining and some lung adenocarcinomas are TTF-1 negative, so the result must always be interpreted in context with imaging and the full marker panel.